Rockland produces new Anti-NF-κB monoclonal antibody

Rockland Immunochemicals (www.rockland-inc.com) has produced a new Anti-NF-κB monoclonal antibody (catalog number 200-301-065) validated by several assays relevant for discovery including immunofluorescence microscopy (IF), immunohistochemistry (IHC), western blotting (WB) and ELISA (E).

The NF-κB p65 antibody was produced by using our electrofusion hybridoma technology. NF-κB is located in the cytosol complexed with the inhibitory protein IκBα. In response to extracellular stimuli the inhibitory molecule is marked for degradation releasing NF-κB which then translocates to the nucleus and binds to target gene sequences. NF-κB has been linked to cancer, inflammatory and autoimmune diseases, septic shock, viral infection, and improper immune development. NF-κB is a key target for drug discovery. Aberrant activation of NF-κB is frequently observed in many cancers.

Rockland is excited about the commercial success of its monoclonal Anti-NF-κB p65 (Rel A) antibody. This antibody will enhance our existing portfolio of reagents that investigate NF-κB Signaling.

Rockland produces other NF-κB antibodies including Anti-IKBα and Anti-NF-κB p65 pS276.

Source: Rockland Immunochemicals